Does Comparative-Effectiveness Research Threaten Personalized Medicine?
Authors:
- Sean R. TunisSTSean R. Tunis
- 7 May 2009
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 360 (19) , 1925-1927
Abstract
The American Reinvestment and Recovery Act gives comparative-effectiveness research (CER) a large boost in funding over the next 2 years. Despite a consensus that better information about the relative effectiveness of different medical interventions is needed to improve the quality and value of care, some view CER with skepticism. Recently, the Partnership to Improve Patient Care, a coalition of 36 industry, patient-advocacy, and clinician organizations, raised concerns that CER will not take adequate account of individual patient differences and may impede the development and adoption of improvements in medical care and “stymie progress in personalized medicine.”1Keywords
This publication has 4 references indexed in Scilit:
- Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trialsThe Lancet, 2009
- Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3Annals of Internal Medicine, 2009
- Pharmacogenomics — Ready for Prime Time?New England Journal of Medicine, 2008
- Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral AnticoagulationCirculation, 2007